Key Highlights
- SCADE boosts AI performance in genomics with over 96% code execution success
- Trained on tens of millions of high-quality single cells for unparalleled accuracy
- Customizable for neurology, oncology, microbiology, and immunology applications
Source: Direct
Notable Quote
- “Our goal is to enable scientists such as biologists and biochemists to perform genomics and bioinformatics without writing computer code. AI-driven platforms like SCADE are no longer just ‘nice to have’; they are rapidly becoming the foundation upon which modern genomic science stands.” — Bardia Nezami, CEO at Valted Seq, Inc
Why This Matters
The launch of SCADE represents a pivotal advancement in precision medicine, offering a scalable, user-friendly platform for decoding complex genomic data. By integrating domain-specific AI trained on in-house-generated single cell datasets, Valted Seq addresses the long-standing limitations in accuracy and scalability faced by generic AI models. This breakthrough not only accelerates drug and biomarker discovery but also brings the vision of personalized medicine closer to reality for researchers, pharmaceutical companies, and clinicians worldwide.
